Pulmonary/Respiratory Medicine CME

Credits: 1.00 CME
Penn State College of Medicine
Winning Strategies for Diagnosing and Managing Chronic Obstructive Pulmonary Disease
Fernando J. Martinez, MD, MS
29 November, 2019
Credits: 1.00 CME
Penn State College of Medicine
Living With Severe Asthma: Understanding the Patient Experience to Guide Therapeutic Decision-Making
Nicola A. Hanania, MD, MS
29 November, 2019
Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
Challenges, Controversies, and Opportunities in the Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases: Working Together to Improve Patient Outcomes
Kathryn Beal, MD / Sandip Patel, MD
4 November, 2019
Credits: 1.50 CME
Purdue University College of Pharmacy
Teaming Up to Overcome Challenges in Severe Asthma Management: The Role of Targeted Therapy in Personalized Care
William J. Calhoun, MD / Neil S. Skolnik, MD
29 October, 2019
Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer
Roy H. Decker, MD, PhD
21 October, 2019
Credits: 1.00 CME / MOC / CNE / CPE
Medical Learning Institute, Inc.
Improving the Diagnosis, Treatment, and Outcomes of Patients With HAP and VAP: A Critical Look at Current Guidelines and New Treatment Options
Andrew F. Shorr, MD, MPH, MBA, FACP, FCCP
17 October, 2019
Credits: 0.50 CME
University of Cincinnati
Relieving the Burden of EGPA: Examining the Latest Advances in Diagnosis and Treatment
Michael E. Wechsler, MD
24 September, 2019
Credits: 0.50 CME
Medical Learning Institute, Inc.
A Visual Guide to Timely and Accurate Diagnosis of Idiopathic Pulmonary Fibrosis
Paul W. Noble, MD
4 September, 2019
Credits: 1.00 CME / MOC / CNE / CPE
Medical Learning Institute, Inc.
Applying New Insights to Improve Diagnosis and Management of Interstitial Lung Diseases
Amy L. Olson, MD, MSPH
1 August, 2019
Credits: 0.75 CME / MOC / CNE
Medical Learning Institute, Inc.
Expanding Treatment Choices in Mesothelioma: Exploring the Promise of Tumor Treating Fields and Novel Systemic Approaches to Optimize Patient Outcomes
Charles B. Simone, MD, FACRO
29 July, 2019
Credits: 0.50 CME
Medical Learning Institute, Inc.
Advances in the Treatment of Uncontrolled Persistent Asthma: Expert Insights in Personalizing Patient Care
Michael E. Wechsler, MD
25 July, 2019
Credits: 1.50 CME
Medical Learning Institute, Inc.
Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient
Benjamin Levy, MD
25 July, 2019
Credits: 1.00 CME
Medical Learning Institute, Inc.
Systemic Sclerosis–Associated Interstitial Lung Disease: Expert Insights on Early Diagnosis and Optimal Management
Marilyn K. Glassberg, MD
8 July, 2019
Credits: 0.50 CME
Medical Learning Institute, Inc.
The Latest Evidence on Treatment for Uncontrolled Persistent Asthma: Breaking News From Dallas
Monica Kraft, MD
5 July, 2019
Credits: 0.50 CME
Medical Learning Institute, Inc.
Advances in the Management of Nontuberculous Mycobacterial Lung Disease (NTM-LD): Expert Insights From Dallas
Doreen Addrizzo-Harris, MD
25 June, 2019
Credits: 1.50 CME / MOC / CNE
Medical Learning Institute, Inc.
The Expanding Role of Immunotherapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Thoracic Surgeons
Jessica Donington, MD
17 June, 2019
Credits: 1.00 CME / MOC / CNE
Medical Learning Institute, Inc.
A New Era Has Begun in the Treatment of SCLC: Navigating Novel Therapeutic Options and Strategies for Improving Patient Outcomes
Stephen V. Liu, MD
29 May, 2019
Credits: 1.50 CME / MOC / CNE
Medical Learning Institute, Inc.
The Present and Future of Immunotherapy as a Key Component of the Treatment Arsenal for Locally Advanced & Earlier Stages of Lung Cancer
Leora Horn, MD, MSc, FRCPC
9 May, 2019
Credits: 1.50 CME / MOC / CNE
Medical Learning Institute, Inc.
Refining Current Practice and Exploring New Frontiers in EGFR-Mutant NSCLC: Evolving Science, New Standards of Care, and Implications for Multidisciplinary Management
Benjamin Levy, MD
17 April, 2019
Credits: 1.50 CME / MOC / CNE
Medical Learning Institute, Inc.
Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges
Scott Antonia, MD, PhD
15 April, 2019
Credits: 1.00 CME / MOC / CNE
Medical Learning Institute, Inc.
Exploring the Path Forward in Nontuberculous Mycobacterial Lung Disease: A MasterClass on Risk Factors, Diagnosis, and Treatment
David Griffith, MD
3 April, 2019
Credits: 1.00 CME / MOC / CNE
Medical Learning Institute, Inc.
Expanding Options and Difficult Choices in the Initial Treatment of Advanced NSCLC: How to Personalize Treatment Decisions in the Era of Immuno-Oncology and Combinations
Mark Socinski, MD
27 March, 2019
Credits: 1.50 CME
Medical Learning Institute, Inc.
Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes
Richard Finn, MD
15 February, 2019
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do
Lynette M. Sholl, MD
6 February, 2019
Credits: 1.00 CME / MOC / CE
Medical Learning Institute, Inc.
The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care
Naiyer Rizvi, MD
14 December, 2018
Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do
Lynette Sholl, MD
11 December, 2018
Credits: 1.50 CME
Medical Learning Institute, Inc.
The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal
Roy Decker, MD, PhD
7 December, 2018